stent trade +price control for stents +companies operate the markets +It is now officially confirmed that a stent can cost the patient over 10 times by the time it moves from the manufacturer to the patient. Incidentally, along with stent companies, it is hospitals and cardiologists who have been most vocal against. Combining of the data for DES along with bioabsorbable stents makes it difficult to get an exact idea of just how much the mark-up on DES alone could be. Hence the margin allowed to dealers ranging from 13% to 196% is said to include the cost of these practices too. The real price to hospitals is often lower.

Source: Times of India January 16, 2017 22:27 UTC